Abstracts Archive - Page 490 of 2425 - ACR Meeting Abstracts

Abstract Number: 2208 • ACR Convergence 2022
Diagnostic Performance of Hip Ultrasound in Calcium Pyrophosphate Deposition Disease
Carina Soto-Fajardo¹, Fabian Carranza-Enriquez², Sinthia Solorzano Flores², Abish Angeles², Paola Flores², Raul Pichardo-Bahena², Luis Javier Jara Quezada², Angélica Peña Ayala², Victor-Manuel Ilizaliturri-Sanchez², Georgios Filippou³ and Carlos Pineda², ¹Instituto Nacional de Rehabilitacion "Luis Guillermo Ibarra Ibarra", Ciudad de México, Mexico, ²Instituto Nacional de Rehabilitacion, Ciudad de México, Mexico, ³Rheumatology Department, Luigi Sacco University Hospital, Siena, Italy
Background/Purpose: Calcium Pyrophosphate Deposition Disease (CPPD) is a chronic and potentially incapacitating disease. The reference standard for its diagnosis is the identification of calcium pyrophosphate…
Abstract Number: 2130 • ACR Convergence 2022
Apremilast in Bio-Naïve Patients with Early Psoriatic Arthritis: A National, Real-Life, Multicenter, Non-Interventional, Prospective, 52-week Cohort Study
Petros P. Sfikakis¹, Dimitrios Vassilopoulos², Gkikas Katsifis³, Georgios Vosvotekas⁴, Theodoros Dimitroulas⁵, Argyro Repa⁶, Grigorios Sakellariou⁷, THEODORA SIMOPOULOU⁸, Athanasios Georgountzos⁹, Andreas Bounas¹⁰, Panagiotis Georgiou¹¹, Evangelia Mole¹², Evangelia Kataxaki¹³, Stamatis Nick Liossis¹⁴, Evangelos Theodorou¹⁵, Christina Antoniadou¹⁶, EVANGELOS THEOTIKOS¹⁷, PANAYIOTIS VLACHOYIANNOPOULOS¹⁸, THEODORA MARKATSELI¹⁹, Angeliki Kekki²⁰, NIKOLAOS ANTONAKOPOULOS²¹ and Dimitrios Boumpas²², ¹Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, ²Clinical Immunology-Rheumatology Unit, 2nd Department of Internal Medicine and Laboratory, National and Kapodistrian University of Athens, School of Medicine, Hippokration General Hospital, Athens, Greece, ³Naval Hospital of Athens, Athens, Greece, ⁴Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece, Thessaloniki, Greece, ⁵4th Department of Internal medicine, Hippokration Hospital, School of medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece, Thessaloniki, Greece, ⁶Rheumatology, Clinical Immunology and Allergy, University of Crete School of Medicine, Heraklion, Crete, Greece, ⁷Department of Rheumatology, 424 General Army Hospital, Thessaloniki, Greece, Thessaloniki, Greece, ⁸Clinic of Rheumatology and Clinical Immunology, University Hospital of Larissa, Larissa, Greece, Larissa, Larisa, Greece, ⁹General Hospital of Athens G. Gennimatas, Athens, Greece, ¹⁰Olympion private General Clinic of Patras, Patras, Greece;, Patra, Akhaia, Greece, ¹¹Rheumatology Unit, Agios Andreas Hospital, Patras, Greece, PATRA, Akhaia, Greece, ¹²Department of Rheumatology, KAT General Hospital of Attica, Athens, Greece, ¹³Rheumatology Unit, Thriasio General Hospital of Elefsina, Magoula, Greece, ¹⁴Division of Rheumatology, Department of Internal Medicine, Patras University Hospital, University of Patras Medical School, Patras, Greece, Patras, Akhaia, Greece, ¹⁵Rheumatology Clinic 251 Hellenic Air Force Hospital, Athens, Greece, ¹⁶First Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece, ¹⁷Rheumatology Department, Asklepieion Voulas General Hospital, Athens, Greece, ¹⁸Department of Pathophysiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece, ¹⁹Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece, ²⁰Genesis Pharma SA, Halandri, Greece, ²¹Genesis Pharma SA, Chalandri, Greece, ²²4th Department of Internal Medicine, "Attikon" University Hospital, Athens, Joint Academic Rheumatology Program, Medical School, National and Kapodistrian University of Athens, Athens, Greece
Background/Purpose: Apremilast is a targeted synthetic disease-modifying anti-rheumatic drug (tsDMARD) approved for psoriatic arthritis (PsA). Few clinical studies assessing treatment regimens in PsA have focused…
Abstract Number: 2122 • ACR Convergence 2022
Bimekizumab Treatment Improves Health-Related Quality of Life in Biologic DMARD-Naïve and TNFi-IR Patients with Active PsA: Pooled 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
Dafna Gladman¹, Lars Erik², Diamant Thaci³, Paolo Gisondi⁴, Laure Gossec⁵, M. Elaine Husni⁶, Alice Gottlieb⁷, Hiroaki Dobashi⁸, Barbara Ink⁹, Deepak Assudani⁹, Rajan Bajracharya⁹, Jason Coarse¹⁰, Jérémy Lambert¹¹ and William Tillett¹², ¹Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ²Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, ³Institute and Comprehensive Center for Inflammation Medicine, University Hospital of Lübeck, Lübeck, Germany, ⁴Dermatology and Venereology, Department of Medicine, Università di Verona, Verona, Italy, Verona, ⁵Sorbonne Université, Paris, France, ⁶Cleveland Clinic, Cleveland, OH, ⁷Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, NY, ⁸Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Raleigh, NC, USA, Raleigh, NC, ¹¹UCB Pharma, Colombes, France, Irigny, France, ¹²Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: PsA imparts a substantial burden on patient health-related quality of life (HRQoL).1 Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition…
Abstract Number: 2124 • ACR Convergence 2022
Immunological Differences Between PsA Patients Who Are Tumor Necrosis Factor Inhibitor-Naïve and Who Have Inadequate Response to Tumor Necrosis Factor Inhibitors
Stefan Siebert¹, Laura Coates², Georg Schett³, Siba P. Raychaudhuri⁴, Warner Chen⁵, Sheng Gao⁵, Soumya Chakravarty⁶, May Shawi⁷, Frederic Lavie⁸, Elke Theander⁹, Marlies Neuhold¹⁰, Alexa Kollmeier¹¹, Xie L Xu¹², Proton Rahman¹³, Philip J Mease¹⁴ and Atul Deodhar¹⁵, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, Scotland, United Kingdom, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³Universitätsklinikum Erlangen, Erlangen, Germany, ⁴Rheumatology, Allergy, and Clinical Immunology, University of California Davis, School of Medicine, Sacramento, CA, ⁵Janssen Research and Development, LLC, Spring House, PA, ⁶Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, ⁷Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁸The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, Paris, France, ⁹Janssen Cilag, Lund, Sweden, ¹⁰Janssen, Zug, Switzerland, ¹¹Janssen-Cilag, Research & Development, LLC, San Diego, CA, ¹²Janssen Research & Development, LLC, San Diego, CA, USA, San Marcos, CA, ¹³Memorial University, St. John's, NL, Canada, ¹⁴Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ¹⁵Oregon Health & Science University, Portland, OR, USA, Portland, OR
Background/Purpose: A better understanding of the immunological differences between psoriatic arthritis (PsA) patients (pts) who are tumor necrosis factor inhibitor (TNFi)-naïve and who have inadequate…
Abstract Number: PP13 • ACR Convergence 2022
How Becoming Engaged in My Care with Specialized Tools and Support Helped Me Find My Personal Lupus Triggers and Regain Control of My Health
Tonya Hinton-Green, Philadelphia, PA
Background/Purpose: My story begins in the ER where I was diagnosed with lupus right after my 22nd birthday.For the next 25 years I went from…
Abstract Number: PP21 • ACR Convergence 2022
What Lies Beneath: Making Rheumatoid Arthritis Visible for the Seronegative Patient Through Blood Work
Shilpa Venkatachalam, Global Healthy Living Foundation, New York, NY
Background/Purpose: When I first received my Rheumatoid Arthritis (RA) diagnosis 5 years ago, I experienced a combination of relief and disbelief. Relief because now all…
Abstract Number: PP26 • ACR Convergence 2022
Chronically Catherine: A Sex and the City-Inspired Autobiographical Column for Disabled Young Adults on Subjects We Really Care About – Like Disabled Dating and How Hot Cheetos Saved My Life
Catherine Ames¹, Courtney Wells² and Kristine Carandang¹, ¹Young Patients' Autoimmune Research & Empowerment Alliance, San Diego, CA, ²University of Wisconsin-River Falls; Young Patients' Autoimmune Research and Empowerment Alliance, St. Paul, MN
Background/Purpose: What if Carrie Bradshaw, sex advice columnist, fashionsta, and all around icon from Sex and the City were chronically ill? Or disabled? That's the…
Abstract Number: PP24 • ACR Convergence 2022
Planting Seeds of Self-Advocacy: Increasing Healthcare Engagement in Children and Adolescents Through Arthritis Camp
Kaye Anderson¹, Kristine Carandang² and Courtney Wells³, ¹Young Patients' Autoimmune Research & Empowerment Alliance, River Falls, WI, ²Young Patients' Autoimmune Research & Empowerment Alliance, San Diego, CA, ³University of Wisconsin-River Falls; Young Patients' Autoimmune Research and Empowerment Alliance, St. Paul, MN
Background/Purpose: I was diagnosed with Juvenile Idiopathic Arthritis at the age of ten. The constant battle between doctor appointments, pain, and medication side effects left…
Abstract Number: PP15 • ACR Convergence 2022
Coordination of Care by a Healthcare Team for Unexpected and Unusual Side Effects Occurring During a Global Pandemic
Laura Genoves, Arthritis Foundation, Bainbridge Island, WA
Background/Purpose: I am a patient who lives with moderate to severe RA. My quality of life is dependent on medications such as a biologic, DMARDs…
Abstract Number: PP16 • ACR Convergence 2022
Please Hear Me: How Effective Provider-Patient Communication Improved My Psoriatic Arthritis
Ashley Krivohlavek, Oklahoma City, OK
Background/Purpose: At age 12, I was diagnosed with psoriasis (PsO) followed by a diagnosis of psoriatic arthritis (PsA) at age 30. I'm now 38. In…
Abstract Number: PP11 • ACR Convergence 2022
Exercise as a Supportive Treatment for My Ankylosing Spondylitis
Sara King-Dowling, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Patients with autoimmune rheumatic diseases (ARDs) are often caught in a paradox as they experience mobility challenges, but long periods of immobility cause increased…
Abstract Number: PP06 • ACR Convergence 2022
Search for a New Rheumatologist; What Happened When My Trusted Rheumatologist Retired
Lawrence Phillips, Noblesville, IN
Background/Purpose: I was diagnosed with rheumatoid arthritis (RA) in 1999. In 2015 and 2019, two surgeons independently diagnosed me with ankylosing spondylitis (AS) following two…
Abstract Number: PP09 • ACR Convergence 2022
A Matter of Life and Death: Why Diversity, Equity and Inclusion Matter for Health Care Providers
Tonya Horton, Rutgers University, Cherry Hill, NJ
Background/Purpose: In 2017, I went from exercising daily to hardly able to walk due to severe knee pain. My primary care doctor ordered x-rays and…
Abstract Number: 1785 • ACR Convergence 2022
PROs and Sociodemographic Factors in Year Prior to COVID Predict Trajectories of Depressive Symptoms in Adults with RA in First 2 Years of Pandemic: Data from the Canadian Early Arthritis Cohort
Susan Bartlett¹, orit schieir², Marie-France Valois², Janet Pope³, Louis Bessette⁴, Gilles Boire⁵, Carol Hitchon⁶, Edward Keystone⁷, Carter Thorne⁸, Diane Tin⁹, Glen Hazlewood¹⁰ and Vivian Bykerk¹¹, ¹McGill University, Montreal, QC, Canada, ²McGill University, Montréal, QC, Canada, ³University of Western Ontario, London, ON, Canada, ⁴Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, ⁵Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁸Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹The Arthritis Program Research Group, Newmarket, ON, Canada, ¹⁰University of Calgary, Calgary, AB, Canada, ¹¹Hospital for Special Surgery, New York, NY
Background/Purpose: Growing evidence points to considerable mental health impacts of the prolonged COVID-19 pandemic, though data from longitudinal studies in rheumatic diseases are sparse. We…
Abstract Number: 1786 • ACR Convergence 2022
Anterior Knee Pain Is Associated with 2-year Compartment Specific Patellofemoral Cartilage Worsening: The MOST Study
Corey Lanois¹, Natalie Collins², Tuhina Neogi³, Ali Guermazi⁴, Frank Roemer⁵, Michael LaValley⁶, Michael Nevitt⁷, James Torner⁸, Cora E. Lewis⁹ and Joshua Stefanik¹⁰, ¹Northeastern University, Providence, RI, ²University of Queensland, Brisbane, Australia, ³Boston University School of Medicine, Boston, MA, ⁴Boston University, Boston, MA, ⁵Friedrich-Alexander University Erlangen Nürnberg, Erlangen, Germany, ⁶Boston University School of Public Health, Arlington, MA, ⁷University of California at San Francisco, Orinda, CA, ⁸University of Iowa, Iowa City, IA, ⁹University of Alabama at Birmingham, Birmingham, AL, ¹⁰Northeastern University, Boston, MA
Background/Purpose: Anterior knee pain (AKP) may be a precursor to patellofemoral osteoarthritis (PFOA). Cross-sectionally, frequent AKP has been associated with MRI features of PFOA; however,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].